<DOC>
	<DOCNO>NCT01923181</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial examine dose range , escalation efficacy oral semaglutide subject type 2 diabetes .</brief_summary>
	<brief_title>Multiple Dose Trial Examining Dose Range , Escalation Efficacy Oral Semaglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>BMI equal 25 equal 40 kg/m^2 Subjects diagnose T2D ( Type 2 diabetes ) treat diet exercise and/or stable dose metformin least 30 day prior screen HbA1c 7.09.5 % ( 5380 mmol/mol ) ( inclusive ) Subjects select oral medication narrow therapeutic window , warfarin , digoxin , tricyclic antidepressant , lithium , aminophylline , theophylline anticonvulsant History chronic pancreatitis idiopathic acute pancreatitis Chronic malabsorption , regardless aetiology History Crohn 's disease , ulcerative colitis , inflammatory bowel disease Treatment glucose lower agent ( ) metformin state inclusion criterion period 90 day screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>